Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis

被引:31
|
作者
Ingwersen, Jens [1 ]
Aktas, Orhan [1 ]
Hartung, Hans-Peter [1 ]
机构
[1] Univ Dusseldorf, Univ Hosp, Fac Med, Dept Neurol, Dusseldorf, Germany
关键词
Relapsing-remitting multiple sclerosis; Disease-modifying therapy; Treatment decisions; Treatment algorithm; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PLACEBO-CONTROLLED PHASE-3; RELEASE DIMETHYL FUMARATE; DOUBLE-BLIND; INTERFERON-BETA; DISEASE-ACTIVITY; INTRAMUSCULAR INTERFERON; DIAGNOSTIC-CRITERIA; ORAL TERIFLUNOMIDE; GLATIRAMER ACETATE;
D O I
10.1007/s13311-015-0412-4
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Treatment options in relapsing-remitting multiple sclerosis have increased considerably in recent years; currently, a dozen different preparations of disease-modifying therapies are available and some more are expected to be marketed soon. For the treating neurologist this broad therapeutic repertoire not only greatly improves individualized management of the disease, but also makes choices more complex and difficult. A number of factors must be considered, including disease activity and severity, safety profile, and patient preference. We here discuss the currently existing options and suggest treatment algorithms for managing relapsing-remitting multiple sclerosis.
引用
收藏
页码:47 / 57
页数:11
相关论文
共 50 条
  • [1] Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis
    Jens Ingwersen
    Orhan Aktas
    Hans-Peter Hartung
    [J]. Neurotherapeutics, 2016, 13 : 47 - 57
  • [2] Advances in the treatment of relapsing-remitting multiple sclerosis - critical appraisal of fingolimod
    Gasperini, Claudio
    Ruggieri, Serena
    Mancinelli, Chiara Rosa
    Pozzilli, Carlo
    [J]. THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2013, 9 : 73 - 85
  • [3] Daclizumab for the treatment of relapsing-remitting multiple sclerosis
    Herwerth, Marina
    Hemmer, Bernhard
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2017, 17 (06) : 747 - 753
  • [4] Alemtuzumab in the treatment of relapsing-remitting multiple sclerosis
    Fox, Edward J.
    [J]. EXPERT REVIEW OF NEUROTHERAPEUTICS, 2010, 10 (12) : 1789 - 1797
  • [5] Ocrelizumab for the treatment of relapsing-remitting multiple sclerosis
    Menge, Til
    Dubey, Divyanshu
    Warnke, Clemens
    Hartung, Hans-Peter
    Stuve, Olaf
    [J]. EXPERT REVIEW OF NEUROTHERAPEUTICS, 2016, 16 (10) : 1131 - 1139
  • [6] Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis
    Hersh, Carrie M.
    Cohen, Jeffrey A.
    [J]. IMMUNOTHERAPY, 2014, 6 (03) : 249 - 259
  • [7] Considerations in the treatment of relapsing-remitting multiple sclerosis
    Calabresi, PA
    [J]. NEUROLOGY, 2002, 58 (08) : S10 - S22
  • [8] Teriflunomide for the treatment of relapsing-remitting multiple sclerosis
    Miller, Aaron E.
    [J]. EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2015, 11 (02) : 181 - 194
  • [9] Ponesimod for the treatment of relapsing-remitting multiple sclerosis
    Gaber, Tarek A-Z K.
    Eltemamy, Marwa
    [J]. PROGRESS IN NEUROLOGY AND PSYCHIATRY, 2022, 26 (02) : 18 - 19
  • [10] Relapsing-remitting multiple sclerosis
    Flores, A
    Ochoa, E
    Zamora, S
    Barrientos, UN
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2003, 214 (1-2) : 110 - 110